1060 Optimally engineered IL18 Fc-fusion proteins balance potency and pharmacokinetics to promote strong anti-tumor activity

• Christine Bonzon,
• Rumana Rashid,
• Irene Leung,
• Nicole Rodriguez,
• Alex Nisthal,
• Ruschelle Love,
• Sung-Hyung Lee,
• Panida Lertkiatmongkol,
• Sher Karki,
• Kendra N Avery,
• Norman J Barlow,
• Seung Y Chu,
• Gregory L Moore,
• John R Desjarlais

Affiliations

Christine Bonzon

Aff391 Xencor Inc. Monrovia CA USA

Rumana Rashid

Aff390 Xencor, Inc. Monrovia CA USA

Irene Leung

Moorfields Ophthalmic Reading Centre, NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK

Nicole Rodriguez

Xencor, Inc., Pasadena, CA, USA

Alex Nisthal

Xencor, Inc., Monrovia, CA, USA

Ruschelle Love

1Xencor, Inc., Monrovia, CA, United States

Sung-Hyung Lee

Xencor, Inc., Pasadena, CA, USA

Panida Lertkiatmongkol

Xencor, Monrovia, CA, USA

Sher Karki

Xencor, Monrovia, CA, USA

Kendra N Avery

Xencor, Inc., Pasadena, CA, USA

Norman J Barlow

Xencor, Inc., Pasadena, CA, USA

Seung Y Chu

Xencor, Inc., Pasadena, CA, USA

Gregory L Moore

Xencor, Inc., Pasadena, CA, USA

John R Desjarlais

Xencor, Inc., Pasadena, CA, USA